(Vienna, Austria) The annual societal cost of Parkinson's disease across Europe reached €22.8 billion in 2019, equivalent to €28.8 billion at 2025 prices, a new study published today in Movement Disorders has shown.¹ As the number of people living with Parkinson's disease continues to grow, researchers warn that health and social care systems are likely to face increasing pressure.
The research estimated that approximately 2.2 million adults were living with Parkinson's disease across 47 European countries in 2019. The condition resulted in €17.3 billion of direct medical and non-medical costs, €4.4 billion in unpaid informal care provided by family members and friends and a further €1 billion in indirect costs due to lost productivity.¹
Parkinson's disease is the world's second most common and fastest-growing neurodegenerative disorder. 2,3 Its prevalence in Europe has nearly doubled since 1990, rising from 135 to 247 cases per 100,000 people. 4 This increase has been driven by an ageing population, alongside improved disease recognition and advances in diagnosis . 2,5
The study found that direct medical and non-medical costs, such as hospital care, medications, social care and home adaptations, accounted for more than three-quarters (76%) of the total economic burden of Parkinson's disease. These findings underscore the substantial demands the condition places on health and social care systems.
Informal care represented almost one-fifth (19%) of the total burden, highlighting the essential role played by family members, friends and other unpaid caregivers in supporting people living with Parkinson's disease.
Günther Deuschl, Senior Professor and founding president of the European Academy of Neurology (EAN), commented, “Studies in different countries have already shown that Parkinson’s disease is costly, but this study has provided a detailed account of the disease burden in Europe by modelling the costs for every European country based on all available evidence.”
The research forms part of the Cost of Illness in Neurology in Europe (COIN-Eu) initiative, led by the EAN, which aims to quantify the societal and economic burden of major neurological diseases across Europe. Researchers combined prevalence estimates from the Global Burden of Disease Study 6 with cost data identified through a systematic review of published European cost-of-illness studies to estimate the annual economic burden of Parkinson’s disease.
Overall, Germany recorded the highest national costs at €5.7 billion, followed by France (€5.3 billion), Italy (€2.6 billion), Spain (€1.9 billion) and the United Kingdom (€1.6 billion). Together, these five countries accounted for approximately 75% of the total economic burden of Parkinson's disease across Europe.
“These figures reflect not only the number of people living with Parkinson's disease, but also the quality and cost of the care they receive”, explained Professor Richard Dodel from the University Duisburg-Essen. “The concentration of costs in these five countries is likely due to a combination of their large populations, higher age-related prevalence of Parkinson's disease, higher healthcare costs in wealthier countries and the greater availability of data, rather than any single factor.”
The study also identified important evidence gaps. Of the 14 eligible cost studies included in the analysis, 13 came from high-income countries, and no eligible primary cost data were available from lower-middle-income countries, meaning the economic burden could not be estimated for those nations. Consequently, the €22.8 billion estimate covers 43 of the 47 countries assessed for prevalence. The authors emphasise the need for more standardised methods of measuring Parkinson's disease costs to produce more consistent and comparable evidence and support future healthcare planning and policy decisions.
"These findings provide policymakers, healthcare planners and the neurological community with important evidence to better understand the growing burden of Parkinson's disease and to plan for future care needs", concluded Professor Günther Deuschl. "The EAN will continue to monitor the burden and costs of neurological diseases as part of our mission to improve the lives of people living with neurological conditions."
ENDS
Notes to Editors:
Press Enquiries:
A reference to the EAN must be included when communicating the information within this press release.
For further information or to speak to an expert, please contact the press team at press@ean.org .
About the Expert:
Prof. Günther Deuschl is Senior Professor of Neurology at Kiel University, Germany, and former Head of the Department of Neurology at the Christian-Albrechts University of Kiel. He is internationally recognised for his pioneering work in Parkinson’s disease, tremor, movement disorders, and deep brain stimulation, and served as the founding President of the European Academy of Neurology (EAN).
Prof. Richard Dodel is Professor of Geriatrics and Neurology at the University of Duisburg–Essen, Germany. His research focuses on neurodegenerative diseases, dementia, Parkinson’s disease and clinical trials. He an internationally known expert for health-care research and economic aspects of neurological disorders.
About the Study:
The Parkinson's disease analysis forms part of the C osts o f I llness in N eurology in Europe (COIN-Eu) project, a European initiative led by the European Academy of Neurology (EAN) that aims to assess the societal and economic burden of major neurological diseases across Europe.
Researchers combined 2019 prevalence estimates from the Global Burden of Disease Study with cost data identified through a systematic review of published European cost-of-illness studies, identifying 14 eligible publications. Where country-level cost data were unavailable, costs were imputed using World Bank gross national income categories and country-specific economic indicators. All costs were standardised to 2019 values and converted to euros using purchasing power parities. The estimates were validated by clinical experts affiliated with the EAN.
Costs were estimated across three categories:
Prevalence was assessed across all 47 EAN member countries. Cost estimates were generated for 43 of these countries (30 high-income and 13 upper-middle-income countries), as no eligible primary cost data were available for lower-middle-income countries.
About the EAN:
The EAN is a non-profit, independent organisation representing more than 45,000 members, as well as 48 European national societies. As a medical society, we promote excellence in the practice of general neurology throughout Europe, leading to improved patient care.
We also aim to keep Europe at the forefront of neurological research and maintain its position as one of the world’s leading scientific hotspots in neurology.
Learn more: ean.org
References:
Movement Disorders
28-Aug-2026